TESARO, Inc. (NASDAQ:TSRO) has been assigned a $124.00 price objective by equities researchers at Jefferies Group LLC in a report issued on Thursday. The brokerage currently has a “hold” rating on the biopharmaceutical company’s stock. Jefferies Group LLC’s price target suggests a potential upside of 13.71% from the stock’s current price.

Several other analysts also recently weighed in on the stock. Credit Suisse Group set a $190.00 price objective on shares of TESARO and gave the stock a “buy” rating in a research report on Friday. Evercore ISI started coverage on shares of TESARO in a research report on Wednesday. They issued an “in-line” rating and a $121.00 price target for the company. Robert W. Baird reiterated a “neutral” rating and issued a $140.00 price target (down previously from $155.00) on shares of TESARO in a research report on Thursday, August 10th. Morgan Stanley reiterated an “overweight” rating and issued a $183.00 price target on shares of TESARO in a research report on Thursday, August 10th. Finally, ValuEngine raised shares of TESARO from a “sell” rating to a “hold” rating in a research note on Tuesday, August 1st. One analyst has rated the stock with a sell rating, eleven have given a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $173.47.

TESARO (NASDAQ TSRO) traded up 1.65% during midday trading on Thursday, reaching $110.85. 394,208 shares of the company were exchanged. The firm has a 50-day moving average price of $126.76 and a 200-day moving average price of $148.14. The company’s market capitalization is $6.01 billion. TESARO has a 52 week low of $83.26 and a 52 week high of $192.94.

TESARO (NASDAQ:TSRO) last issued its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($2.82) earnings per share for the quarter, missing the consensus estimate of ($2.52) by $0.30. The company had revenue of $29.50 million for the quarter, compared to analysts’ expectations of $18.61 million. TESARO had a negative return on equity of 104.00% and a negative net margin of 1,301.19%. The firm’s quarterly revenue was down 17.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($1.28) EPS. Equities research analysts anticipate that TESARO will post ($8.68) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally published by American Banking News and is owned by of American Banking News. If you are accessing this piece of content on another publication, it was illegally copied and republished in violation of US and international copyright laws. The original version of this piece of content can be read at https://www.americanbankingnews.com/2017/08/18/jefferies-group-llc-reiterates-124-00-price-target-for-tesaro-inc-tsro.html.

In other news, VP Edward C. English sold 8,500 shares of the firm’s stock in a transaction that occurred on Tuesday, June 6th. The shares were sold at an average price of $138.65, for a total transaction of $1,178,525.00. Following the completion of the sale, the vice president now owns 5,396 shares of the company’s stock, valued at $748,155.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 40.50% of the stock is currently owned by company insiders.

Several hedge funds have recently added to or reduced their stakes in the company. Vident Investment Advisory LLC bought a new stake in TESARO during the first quarter worth $351,000. Botty Investors LLC bought a new stake in TESARO during the second quarter worth $140,000. Meeder Asset Management Inc. bought a new stake in TESARO during the first quarter worth $177,000. Nordea Investment Management AB bought a new stake in TESARO during the second quarter worth $167,000. Finally, Oppenheimer Asset Management Inc. increased its stake in TESARO by 3,042.6% in the second quarter. Oppenheimer Asset Management Inc. now owns 1,477 shares of the biopharmaceutical company’s stock worth $206,000 after buying an additional 1,430 shares during the last quarter.

TESARO Company Profile

TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.

Analyst Recommendations for TESARO (NASDAQ:TSRO)

Receive News & Ratings for TESARO Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO Inc. and related companies with MarketBeat.com's FREE daily email newsletter.